 The receptor increase on cancerous cells has been document as two to twelve times that of healthy cells.This greatly increases the selectivity of the drug as the majority of the dose is sequestered in cancerous tissues, bypassing most healthy cells.This effect contributes to the lower toxicity that is associated to the ruthenium drugs in comparison to platinum.